1、 LI T Y, LIU W., CHEN K, et al. The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review [J]. J Clin Pharm Ther,2017,42(2): 135-146. LI T Y, LIU W., CHEN K, et al. The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review [J]. J Clin Pharm Ther,2017,42(2): 135-146.
2、 PURKINS L, WOOD N, KLEINERMANS D, et al.. Effet of food on the pharmacokinetics of multiple-dose oral voriconazole [J]. Br J Clin Pharmacol,2003,56(1): 17-23. PURKINS L, WOOD N, KLEINERMANS D, et al.. Effet of food on the pharmacokinetics of multiple-dose oral voriconazole [J]. Br J Clin Pharmacol,2003,56(1): 17-23.
3、 刘克辛主编,临床药物代谢动力学(案例版) [M]. 3版.北京: 科学出版社,2016: 9. 刘克辛主编,临床药物代谢动力学(案例版) [M]. 3版.北京: 科学出版社,2016: 9.
4、 WANG T T,ZHU H F,SUN J Y,et al. Efficaacy and safety of voriconazoleand CYP2C19 polymorphism for optimized dosage regimens in patients with invasive fungal infections [J]. Int J Antimicrob Agents,2014,44(5): 436-442. WANG T T,ZHU H F,SUN J Y,et al. Efficaacy and safety of voriconazoleand CYP2C19 polymorphism for optimized dosage regimens in patients with invasive fungal infections [J]. Int J Antimicrob Agents,2014,44(5): 436-442.
5、 LI X, YU C, WANG T, CHEN K.,et al. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis [J]. Eur J Clin Pharmacol,2016,72(10): 1185-1193. LI X, YU C, WANG T, CHEN K.,et al. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis [J]. Eur J Clin Pharmacol,2016,72(10): 1185-1193.
6、 OWUSU O A, EGELUND E F, ALSULTAN A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementationof pharmacogenomics? [J]. Pharmacother,2014,34(7): 703-718. OWUSU O A, EGELUND E F, ALSULTAN A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementationof pharmacogenomics? [J]. Pharmacother,2014,34(7): 703-718.
7、 MATSUMOTO K,IKAWAK K .ABEMATSUK K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes [J]. Int J Antimicrob Agents,2009,34(I): 91-94. MATSUMOTO K,IKAWAK K .ABEMATSUK K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes [J]. Int J Antimicrob Agents,2009,34(I): 91-94.
8、 HYLAND R. JONES B C, SMITH D A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J]. Drug Metab Dispos,2003,31(5): 540-547. HYLAND R. JONES B C, SMITH D A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J]. Drug Metab Dispos,2003,31(5): 540-547.
9、 薛阳,李红磊,张薇. 伏立康唑抗真菌作用研究进展 [J]. 人民军医,2016,59(7): 746-748. 薛阳,李红磊,张薇. 伏立康唑抗真菌作用研究进展 [J]. 人民军医,2016,59(7): 746-748.
10、 陈江飞,苗彩云,徐萍.抗真菌药伏立康唑的临床药代动力学研究进展 [J]. 中国临床药理学与治疗学,2015,20(9): 1072-1080. 陈江飞,苗彩云,徐萍.抗真菌药伏立康唑的临床药代动力学研究进展 [J]. 中国临床药理学与治疗学,2015,20(9): 1072-1080.
